Novolin N Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The novolin N market research report is one of a series of new reports that provides novolin N market statistics, including novolin N industry global market size, regional shares, competitors with a novolin N market share, detailed novolin N market segments, market trends and opportunities, and any further data you may need to thrive in the novolin N industry. This novolin N market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growth of retail pharmacies, expansion of patient assistance programs, focus on clinical trials, development of new insulin analogues and focus on comprehensive diabetes care. Major trends in the forecast period include shift towards value-based care, shift to long-acting insulins, remote monitoring, advancements in insulin pen technology, and optimizing insulin regimens.

The increasing prevalence of diabetes is expected to drive the growth of the novolin N market. Diabetes is a chronic condition characterized by high blood glucose levels due to the body's inability to produce enough insulin or effectively use the insulin it produces. Factors contributing to the rise in diabetes include unhealthy diets, sedentary lifestyles, rising obesity rates, aging populations, genetic predisposition, and environmental influences. Novolin N is an intermediate-acting insulin that helps regulate blood sugar levels over an extended period, providing a steady release of insulin to manage glucose metabolism and prevent hyperglycemia, especially between meals and overnight. According to the International Diabetes Federation, approximately 537 million adults worldwide were living with diabetes in 2021, and this number is expected to increase to 643 million by 2030 and 783 million by 2045. As a result, the growing prevalence of diabetes is expected to drive the novolin N market.

The rising rates of obesity are also expected to contribute to the growth of the novolin N market. Obesity is defined as having a body mass index (BMI) of 30 or higher, and its prevalence is increasing due to factors such as poor diets, sedentary lifestyles, limited access to healthy food, socioeconomic challenges, and lack of physical activity. Novolin N, an intermediate-acting insulin, helps manage blood sugar levels in individuals with diabetes, which can indirectly assist in managing obesity. By addressing weight gain linked to uncontrolled diabetes and promoting healthier metabolic function, Novolin N, when combined with lifestyle changes, can support weight management. A report by the Centers for Disease Control and Prevention revealed that in 2022, 22 states in the U.S. had an adult obesity rate of 35% or higher, up from 19 states in 2021. As such, the rising obesity rates are driving the growth of the novolin N market.

The continued rise in urbanization is expected to further propel the growth of the novolin N market. Urbanization refers to the increasing movement of populations from rural areas to cities due to factors such as better job opportunities, improved healthcare and education access, infrastructure development, and a higher standard of living. As more people move to urban areas, lifestyle changes contribute to higher diabetes rates, while greater access to healthcare drives the adoption of treatments such as Novolin N. According to a report by the World Bank, 56% of the global population, or 4.4 billion people, lived in urban areas as of 2023, and this trend is expected to continue, with the urban population predicted to double by 2050, reaching nearly 70% of the global population. Therefore, the growing trend of urbanization is driving the growth of the novolin N market.

The key company operating in the novolin N market is Novo Nordisk.

North America was the largest region in the novolin N market in 2024. The regions covered in novolin N report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the novolin N market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Novolin N is a type of insulin used to control blood sugar levels in individuals with diabetes. It is administered via injection to provide long-acting insulin support, lowering blood sugar over a period of 12 to 18 hours, depending on the individual.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main formulations of novolin N include vials, pen devices, and cartridges. Vials are small glass or plastic containers used to store insulin, including Novolin N. The insulin is used for conditions such as type 1 diabetes and type 2 diabetes. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving a range of end users, including adults, geriatrics, and pediatric patients.

The novolin N market consists of sales of novolin N (NPH Insulin), novolin R (regular insulin), and novolin 70/30. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.